The stock of Dyne Therapeutics Inc (DYN) has gone down by -38.25% for the week, with a -46.03% drop in the past month and a -53.04% drop in the past quarter. The volatility ratio for the week is 11.72%, and the volatility levels for the past 30 days are 7.13% for DYN. The simple moving average for the past 20 days is -35.29% for DYN’s stock, with a -52.81% simple moving average for the past 200 days.
Is It Worth Investing in Dyne Therapeutics Inc (NASDAQ: DYN) Right Now?
Additionally, the 36-month beta value for DYN is 1.22. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for DYN is 77.75M and currently, short sellers hold a 13.53% ratio of that float. The average trading volume of DYN on January 14, 2025 was 1.09M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN)’s stock price has decreased by -3.65 compared to its previous closing price of 15.87. However, the company has seen a -38.25% decrease in its stock price over the last five trading sessions. benzinga.com reported 2025-01-10 that On Friday, Dyne Therapeutics, Inc. DYN revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with Robert W. Baird repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to Robert W. Baird is $46 based on the research report published on December 13, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see DYN reach a price target of $45. The rating they have provided for DYN stocks is “Outperform” according to the report published on November 26th, 2024.
JP Morgan gave a rating of “Neutral” to DYN, setting the target price at $35 in the report published on October 24th of the previous year.
DYN Trading at -43.46% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.78% of loss for the given period.
Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 11.72%, as shares sank -44.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.40% lower at present.
During the last 5 trading sessions, DYN fell by -38.25%, which changed the moving average for the period of 200-days by -42.91% in comparison to the 20-day moving average, which settled at $23.63. In addition, Dyne Therapeutics Inc saw -35.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Beskrovnaya Oxana, who sale 2,334 shares at the price of $28.12 back on Dec 11 ’24. After this action, Beskrovnaya Oxana now owns 201,685 shares of Dyne Therapeutics Inc, valued at $65,632 using the latest closing price.
Scalzo Richard William, the SVP, Head of Finance & Admin. of Dyne Therapeutics Inc, sale 1,455 shares at $28.12 during a trade that took place back on Dec 11 ’24, which means that Scalzo Richard William is holding 127,078 shares at $40,915 based on the most recent closing price.
Stock Fundamentals for DYN
Current profitability levels for the company are sitting at:
- -83.02 for the present operating margin
- 0.64 for the gross margin
The net margin for Dyne Therapeutics Inc stands at -77.75. The total capital return value is set at -0.43. Equity return is now at value -68.69, with -60.47 for asset returns.
Currently, EBITDA for the company is -233.48 million with net debt to EBITDA at 1.62. When we switch over and look at the enterprise to sales, we see a ratio of 276.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.02.
Conclusion
In conclusion, Dyne Therapeutics Inc (DYN) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
